VYNE Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

VYNE Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerVYNE

Market Cap22.9M

Cash RunwayRunway > 12 months

Next Catalystn/a

Public Research Snapshot

VYNE Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for FMX103 1.5% in Papulopustular Rosacea (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
VYN201	n/a	n/a	n/a	Public pipeline row
VYN202	autoimmune diseases	n/a	n/a	Public pipeline row
FMX114	Atopic Dermatitis	n/a	Phase 1 \| Phase 2	Public pipeline row
FCD105	Acne Vulgaris	n/a	Phase 2	Public pipeline row
Serlopitant	Pruritus \| Burns	n/a	Phase 2	Public pipeline row
FMX103 1.5%	Papulopustular Rosacea	n/a	Phase 3	Public pipeline row
5 mg Serlopitant Tablets	Pruritus	n/a	Phase 2	Public pipeline row
Comparator: MK0594 5 mg/day	Alcohol Dependence	n/a	Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00835718	Phase 2	TERMINATED	162	2010-03-11
NCT04070755	Phase 1	COMPLETED	56	2016-11-18
NCT02975271	Phase 2	TERMINATED	1	2017-01-17
NCT03276936	Phase 3	COMPLETED	504	2019-01-03
NCT03841331	Phase 2	COMPLETED	233	2019-12-10
NCT04104685	Phase 2	COMPLETED	446	2020-02-28
NCT04927572	Phase 1 \| Phase 2	COMPLETED	21	2022-08-09
NCT06493578	Phase 2	TERMINATED	205	2025-07-10

Scientific Context

literature_publication | Longitudinal analysis of lipid mediators in post-tuberculosis lung disease identifies significant differences.
literature_publication | Nonantibiotic Properties of Tetracyclines in Rosacea and Their Clinical Implications.
literature_publication | Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions.
literature_publication | Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea.
asset_name | 5 mg Serlopitant Tablets

Want the full VYNE research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.